Plain-English translation of NCT06826872 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new blood pressure medication called SPC1001, which combines three commonly used drugs in one pill: candesartan, amlodipine, and indapamide. The study will compare how well this three-in-one medication works compared to two-drug combinations of the same ingredients. Researchers want to see if the medication is safe and effective for people with essential hypertension (high blood pressure that isn't caused by another condition).
Many people with high blood pressure need multiple medications to control it, which can mean taking several pills every day. This trial is testing whether combining three proven blood pressure drugs into one pill could make treatment simpler and work better for patients.
You likely qualify if…
You likely don't qualify if…
If you join, you'll start with a screening visit within 4 weeks before the study officially begins. Then you'll have a 2-week run-in period where you'll take a placebo (inactive pill) and participate in lifestyle counseling. After that, you'll take the study medication or a comparison medication for 8 weeks, with follow-up visits to check your blood pressure and monitor how you're doing.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
South Korea
Phase
Testing effectiveness
Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Enrollment target
~252 participants
Started
June 2024
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years – 75 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
YeongJin Jeong, Master
Shin Poong Pharmaceutical Co. Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.